Skip to main content

Advertisement

Table 3 Pooled safety results of bevacizumab trials for first-line treatment of advanced breast cancer (E2100, AVADO, RIBBON-1 y

From: Regulatory withdrawal of medicines marketed with uncertain benefits: the bevacizumab case study

Severe or life-threatening or fatal adverse events Pooled chemotherapy (n = 982) Pooled bevacizumab plus chemotherapy (n = 1679
% %
Any 23 37
Sensory neuropathy 7.1 10
Hypertension 1.2 9
Febrile neutropenia 3.5 6.5
Venous thromboembolic event 3.8 2.8
Proteinuria 0 2.3
Arterial thromboembolic event 0.3 1.6
Left ventricular systolic dysfunction 1.2 1.5
Hemorrhage 0.4 1.5
Abnormal tissue repair 0.8 1.7
Wound dehiscence 0.3 0.8
Fistula 0.3 0.5
Gastrointestinal perforation   0.5
Reversible posterior leukoencephalopathy syndrome 0 <0.1